Heart Damage Articles & Analysis
11 news found
XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, has an exclusive license from Cornell ...
Over €100 bn euros, or 50% of the total European healthcare budget is spent treating patients with heart diseases. The EIC accelerator was established to support individual start-ups and small companies to develop and scale up game changing innovations. With the EIC support this funding will enable Genome Biologics to accelerate development of its clinical programmes, ...
“COVID-19 has been reported to cause or worsen heart damage, and with the progressive nature of heart failure, delays in treatment can worsen the prognosis for patients. ...
XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize ...
There was a significant reduction of scar tissue in the damaged heart muscle, which conveyed a reduced likelihood of developing heart failure. ...
The publication, performed in a pig model for the study of chronic myocardial infarction, evidence for the first time that regeneration of the damaged tissue in the heart – responsible for chronic ischemic heart failure – is possible. ...
Treatment of patients undergoing coronary artery bypass surgery resulted in a postoperative reduction of the heart damage marker troponin I. In models of PAH it was shown that Elafin reverses obliterative changes in arteries of lung explants from PAH patients and that treatment with Elafin leads to the regression of pulmonary vascular lesions in rats. ...
Treatment of patients undergoing coronary artery bypass surgery resulted in a postoperative reduction of the heart damage marker troponin I. In models of PAH it was shown that Elafin reverses obliterative changes in arteries of lung explants from PAH patients and that treatment with Elafin leads to the regression of pulmonary vascular lesions in rats. ...
Tricuspid insufficiency is a common disease in patients with heart valve damage. In the presence of significant tricuspid leakage, the probability of mortality increases if it is not corrected. ...
The SQuEEZ technology is based on the ability to track the heart wall as it moves during the contraction of the heart to allow quantitative assessment of regional heart wall motion from cardiac CT data. ...
CardioWise, Inc. has received a National Science Foundation (NSF) Phase IB Small Business Innovation Research grant of $30,000 to continue the development and commercialization of a non-invasive analysis method for detection of heart disease. This award follows and builds on the successful achievement of milestones in a Phase I grant of $150,000 received by the company in ...